In the NAFLD cohort, the G/G‐genotype of PNPLA3 was associated with a higher risk of NASH in both crude (OR 3.42, 95% CI = 1.68–6.95) and adjusted analyses (aOR 3.67, 95% CI = 1.66–8.08), while no association with any allele type of TM6SF2, MBOAT7 or GCKR and the presence of NASH was seen. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.